07:21 AM EST, 11/25/2024 (MT Newswires) -- Astrazeneca ( AZN ) said Monday that a phase 3 trial of its drug Truqap with abiraterone and androgen deprivation therapy as a potential treatment of certain metastatic prostate cancer showed improvements in primary endpoint of radiographic progression-free survival.

The drug, also called capivasertib, "showed an early trend towards an overall survival improvement" in patients with PTEN-deficient de novo, hormone-sensitive metastatic prostate cancer compared to those who did not receive it, the company said.

The drug combination was tried against abiraterone and androgen deprivation therapy (without Truqap) and placebo.